OTCMKTS:RHHVF Roche (RHHVF) Stock Price, News & Analysis $312.30 -10.76 (-3.33%) As of 03:02 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesShort InterestBuy This Stock About Roche Stock (OTCMKTS:RHHVF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Roche alerts:Sign Up Key Stats Today's Range$312.30▼$323.0650-Day Range$310.73▼$335.4952-Week Range$269.80▼$354.19Volume94 shsAverage Volume7,207 shsMarket CapitalizationN/AP/E Ratio28.89Dividend Yield2.50%Price TargetN/AConsensus RatingN/A Company Overview Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland. Read More Roche Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks3rd Percentile Overall ScoreRHHVF MarketRank™: Roche scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Roche. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Roche is 28.89, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.60.Price to Earnings Ratio vs. SectorThe P/E ratio of Roche is 28.89, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.87. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverRoche has a short interest ratio ("days to cover") of 349.6, which indicates bearish sentiment.Change versus previous monthShort interest in Roche has recently decreased by 6.99%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldRoche pays a meaningful dividend of 3.21%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthRoche does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Roche is 72.16%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about Roche's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares ShortedShort Interest Ratio / Days to CoverRoche has a short interest ratio ("days to cover") of 349.6, which indicates bearish sentiment.Change versus previous monthShort interest in Roche has recently decreased by 6.99%, indicating that investor sentiment is improving significantly. News and Social Media1.0 / 5News Sentiment-0.23 News SentimentRoche has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.04 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Roche this week, compared to 1 article on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Roche insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 29.01% of the stock of Roche is held by institutions.Read more about Roche's insider trading history. Receive RHHVF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roche and its competitors with MarketBeat's FREE daily newsletter. Email Address RHHVF Stock News HeadlinesRoche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAICJuly 28 at 3:14 AM | finance.yahoo.comRoche profit beats forecast on strong sales of cancer, allergy drugsJuly 25, 2025 | uk.finance.yahoo.comYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.July 30 at 2:00 AM | Priority Gold (Ad)Roche provides regulatory update on Elevidys™ gene therapy for Duchenne muscular dystrophy in the EUJuly 25, 2025 | finance.yahoo.comRoche's Itovebi combination for breast cancer gets EU nodJuly 24, 2025 | msn.comFDA rejects Genentec's cancer drug label expansionJuly 18, 2025 | msn.comKepler Capital Remains a Buy on Roche Holding AG (RHHVF)July 14, 2025 | theglobeandmail.comGoldman Sachs Sticks to Their Sell Rating for Roche Holding AG (RHHVF)July 6, 2025 | theglobeandmail.comSee More Headlines RHHVF Stock Analysis - Frequently Asked Questions How have RHHVF shares performed this year? Roche's stock was trading at $280.00 on January 1st, 2025. Since then, RHHVF shares have increased by 11.5% and is now trading at $312.3040. How do I buy shares of Roche? Shares of RHHVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - General Sub-IndustryPersonal Services Current SymbolOTCMKTS:RHHVF CIKN/A Webwww.roche.com Phone(161) 688-1111FaxN/AEmployees103,605Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio28.89 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (OTCMKTS:RHHVF) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredDrone Company Secures Major Defense Contract Amid Sweeping Policy ShiftOn July 10th, the White House and DoD announced a sweeping new directive to fast-track U.S. drone dominance. ...The Tomorrow Investor | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredOne stock to replace Nvidia"I said 'SELL' before this stock dropped 90%. Today, I'm shouting 'BUY NOW' before it's too late." In 2000,...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roche Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Roche With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.